Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an investigational implant called OTX-TIC is a safe and effective procedure to reduce pressure in the eye.

What is the Condition Being Studied?

Glaucoma or Ocular Hypertension

Who Can Participate in the Study?

Adults ages 18+ who:
- Are diagnosed with ocular hypertension or open-angle glaucoma
- Are willing to not use contact lenses for 7 months during the study

For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join the study, you will
- Receive either the FDA-approved implant, DurystaTM, or the study implant, OTX-TIC (it will be decided by chance, like drawing numbers from a hat),
- Be in touch with the study team for about 7 months,
- Visit our clinic at the Duke Eye Center up to 10 times

At various visits, you will answer some questionnaires and have eye exams and vision tests.

Study Details

Full Title
A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT)
Principal Investigator
Glaucoma Specialist
Protocol Number
IRB: PRO00110488
NCT: NCT05335122
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698